CRP and Cancer

  • Waliza Ansar
  • Shyamasree Ghosh


C-reactive protein (CRP) as an acute-phase protein is a marker in inflammation, tissue injury and infection. The role of inflammation and CRP in different cancers is a recent matter of research. Increased CRP level is positively correlated with extent of disease and recurrence in advanced cancer. Its role as an interpreter of survival has been elucidated in melanoma, multiple myeloma, lymphoma, ovarian, renal, pancreatic and gastrointestinal tumors. The testing for CRP levels at the time of diagnosis could help clinicians determine severity of the disease with any adjacent inflammation, the tumor’s state of aggressiveness, or other conditions in the body and help guide therapeutics to improve overall survival. The poor prognosis in patients with different types of solid cancers is correlated with elevated plasma CRP levels. The circulating CRP concentrations has stronger correlation with the severity, extent and progression of many different tumor pathologies and the prognostic significance of these associations are consistent with CRP level. Thus CRP is not just being a marker of disease or an inflammatory biomarker but also it contributes to the pathogenesis of cancer also.


Breast cancer Myeloma Lymphoma Sarcoma Carcinoma Metastasis 


  1. Anant Narayan B, Rohit M, Abdullah F, Amit V, Dwarakanath BS (2010) Cancer biomarkers - current perspectives. Indian J Med Res 132:129–149Google Scholar
  2. Aziz A, Rink M, Gakis G, Kluth LA, Dechet C, Miller F, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, Fisch M, Burger M, Fritsche HM (2014) Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int 93(3):352–360. doi: 10.1159/000362248, Epub 2014 Aug 19CrossRefPubMedGoogle Scholar
  3. Carcereny E, Gallardo E, Navarro A, Gel B, Jansa S, Marrades R, Ramirez J, Casas F, Vinolas N, Monzo M (2007) MicroRNAs in human lung cancer and human lung embryogenesis: p 2–004. J Thorac Oncol 2(8):S483CrossRefGoogle Scholar
  4. Chen W, Wang JB, Abnet CC, Dawsey SM, Fan JH, Yin LY, Yin J, Taylor PR, Qiao YL, Freedman ND (2015) Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case–control study. Cancer Epidemiol Biomarkers Prev 24(2):386–392. doi: 10.1158/1055-9965.EPI-14-1038, Epub 2015 Jan 22CrossRefPubMedPubMedCentralGoogle Scholar
  5. Combariza JF, Lombana M, Pino LE, Arango M (2015) C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer 23(4):1009–1013. doi: 10.1007/s00520-014-2454-2, Epub 2014 Oct 2CrossRefPubMedGoogle Scholar
  6. Dai J, Tang K, Xiao W, Yu G, Zeng J, Li W, Zhang YQ, Xu H, Chen ZQ, Ye ZQ (2014) Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev 15(8):3369–3375CrossRefPubMedGoogle Scholar
  7. Fang S, Wang Y, Sui D1, Liu H1, Ross MI1, Gershenwald JE1, Cormier JN1, Royal RE1, Lucci A1, Schacherer CW1, Gardner JM1, Reveille JD1, Bassett RL1,Wang LE1, Wei Q1, Amos CI1, Lee JE2 (2015) C-reactive protein as a marker of melanoma progression. J Clin Oncol 33(12):1389–1396. doi: 10.1200/JCO.2014.58.0209, Epub 2015 Mar 16
  8. Graff JN, Beer TM, Liu B, Sonpavde G, Taioli E (2015) Pooled analysis of C-reactive protein levels and mortality in prostate cancer patients. Clin Genitourin Cancer 13:e217–e221. pii: S1558-7673(15)00013-0CrossRefPubMedGoogle Scholar
  9. Goyal A, Terry MB, Jin Z, Siegel AB (2014) C-reactive protein and colorectal cancer mortality in U.S. adults. Cancer Epidemiol Biomarkers Prev 23(8):1609–1618. doi: 10.1158/1055-9965.EPI-13-0577, Epub 2014 May 27CrossRefPubMedGoogle Scholar
  10. Hsiao W, Herrel LA, Yu C, Kattan MW, Canter DJ, Carthon BC, Ogan K (2015) Master VA Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma. Int J Urol 22(3):264–270. doi: 10.1111/iju.12672, Epub 2014 Nov 26CrossRefPubMedGoogle Scholar
  11. Huang Y, Feng JF, Liu JS, Chen QX (2015) Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag 11:89–940. doi: 10.2147/TCRM.S70954. eCollection 2015CrossRefPubMedPubMedCentralGoogle Scholar
  12. Inoue D, Ozaka M, Matsuyama M, Yamada I, Takano K, Saiura A, Ishii H (2015) Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreaticcancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol 45(1):61–66. doi: 10.1093/jjco/hyu159, Epub 2014 Oct 23CrossRefPubMedGoogle Scholar
  13. Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X (2014) Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. J Cancer Res Ther 10(Suppl):C160–C166. doi: 10.4103/0973-1482.145854. Oncol Lett. 2015 Jan;9(1):425–429. Epub 2014 Nov 4PubMedGoogle Scholar
  14. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Tajiri H (2014) The addition of C-reactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma. Oncology 86(5–6):308–317. doi: 10.1159/000360704, Epub 2014 Jun 7CrossRefPubMedGoogle Scholar
  15. Kuribayashi K, Motoyama S, Sasaki T, Sato Y, Yoshino K, Wakita A, Imai K, Saito H, Minamiya Y (2014) C-reactive protein reduces the relative number of tumor-associated M2 macrophages and intratumoral angiogenesis in mice. Tohoku J Exp Med 233(4):249–255CrossRefPubMedGoogle Scholar
  16. Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y, Bai L (2014) Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark 14(6):469–481. doi: 10.3233/CBM-140423 PubMedGoogle Scholar
  17. Lindenmann J, Fink-Neuboeck N, Koesslbacher M, Pichler M, Stojakovic T, Roller RE, Maier A, Anegg U, Smolle J, Smolle-Juettner FM (2014) The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. J Surg Oncol 110(6):645–650. doi: 10.1002/jso.23711, Epub 2014 Jun 29CrossRefPubMedGoogle Scholar
  18. Lumachi F, Basso SM, Santeufemia DA, Ermani M, Lo Re G, Chiara GB (2014) Preoperative serum C-reactive protein and its prognostic significance in patients with stage III-IV colorectal cancer. Anticancer Res 34(12):7263–7266PubMedGoogle Scholar
  19. Ni XF, Wu P, Wu CP, Ji M, Wu J, Gu XF, Jiang ZX (2014) Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer. Asia Pac J Clin Oncol 11:e22–e30. doi: 10.1111/ajco.12091. [Epub ahead of print]CrossRefPubMedGoogle Scholar
  20. Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, Bueno-de-Mesquita HB, Jansen EH, Tsilidis KK, Trichopoulou A, Weiderpass E, Wu C, Overvad K, Tjønneland A, Boutron-Ruault MC, Dossus L, Racine A, Kaaks R, Canzian F, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Johansson A, Van Guelpen B, Khaw KT, Wareham N, Peeters PH, Quirós JR, Venceslá García A, Molina-Montes E, Dorronsoro M, Chirlaque MD, Barricarte Gurrea A, Key TJ, Duarte-Salles T, Stepien M, Gunter MJ, Riboli E, Pischon T (2015) Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. Int J Cancer 136(5):1181–1192. doi: 10.1002/ijc.29086. Epub 2014 Jul 28CrossRefPubMedGoogle Scholar
  21. Oliveira KG, von Zeidler SV, Lamas AZ, de Podestá JR, Sena A, Souza ED, Lenzi J, Lemos EM, Gouvea SA, Bissoli NS (2014) Relationship of inflammatory markers and pain in patients with head and neck cancer prior to anticancer therapy. Braz J Med Biol Res 47(7):600–604, Epub 2014 May 30CrossRefPubMedPubMedCentralGoogle Scholar
  22. Omae K, Kondo T, Tanabe K (2015) High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. Urol Oncol 33(2):67.e9–67.e13. doi: 10.1016/j.urolonc.2014.07.004. Epub 2014 Aug 12CrossRefGoogle Scholar
  23. Reang P, Gupta M, Kohli K (2006) Biological response modifiers in cancer. MedGenMed 8(4):33PubMedPubMedCentralGoogle Scholar
  24. Rocha P, Morgan CJ, Templeton AJ, Pond GR, Naik G, Sonpavde G (2014) Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat 37(12):772–776. doi: 10.1159/000369545, Epub 2014 Nov 20CrossRefPubMedGoogle Scholar
  25. Rodriguez-Gil JL, Takita C, Wright J, Reis IM, Zhao W, Lally BE, Hu JJ (2014) Inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 23(9):1873–1883. doi: 10.1158/1055-9965.EPI-14-0263, Epub 2014 Jun 10CrossRefPubMedPubMedCentralGoogle Scholar
  26. Schuster M, Nechansky A, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1(2):138–147Google Scholar
  27. Schnoeller TJ, Steinestel J, Steinestel K, Jentzmik F, Schrader AJ (2015) Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer? Int Urol Nephrol 47:765–770CrossRefPubMedGoogle Scholar
  28. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T, Kimura K, Amano R, Kubo N, Tanaka H, Muguruma K, Ohira M, Hirakawa K (2014) Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology 61(136):2236–2240PubMedGoogle Scholar
  29. Shin JH, Kim CJ, Jeon EJ, Sung CO, Shin HJ, Choi J, Yu E (2015) Overexpression of C-reactive protein as a poor prognostic marker of resectable hepatocellular carcinomas. J Pathol Trans Med 49(2):105–111. doi: 10.4132/jptm.2015.01.19, Epub 2015 Mar 12CrossRefGoogle Scholar
  30. Shishido Y, Fujitani K, Yamamoto K, Hirao M, Tsujinaka T, Sekimoto M (2015) C-reactive protein on postoperative day 3 as a predictor of infectious complications following gastric cancer resection. Gastric CancerGoogle Scholar
  31. Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G, Rahnenführer J, Hengstler JG, Schmidt M (2014) Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One 9(10):e111306. doi: 10.1371/journal.pone.0111306. eCollection 2014CrossRefPubMedPubMedCentralGoogle Scholar
  32. Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N, Smith AM (2015) Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB Oxford 17(4):285–291. doi: 10.1111/hpb.12355, Epub 2014 Nov 27CrossRefPubMedPubMedCentralGoogle Scholar
  33. Su HX, Zhou HH, Wang MY, Cheng J, Zhang SC, Hui F, Chen XZ, Liu SH, Liu QJ, Zhu ZJ, Hu QR, Wu Y, Ji SR (2014) Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk. PLoS One 9(7):e102418. doi: 10.1371/journal.pone.0102418. eCollection 2014CrossRefPubMedPubMedCentralGoogle Scholar
  34. Sugita S, Hozumi T, Yamakawa K, Goto T, Kondo T 2015 White blood cell count and C-reactive protein variations following posterior surgery with intraoperative radiotherapy for spinal metastasis. J Spinal Disord Tech. [Epub ahead of print]Google Scholar
  35. Szturmowicz M, Rudziński P, Kacprzak A, Langfort R, Bestry I, Broniarek-Samson B, Orłowski T (2014) Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21–1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer. Pneumonol Alergol Pol 82(5):422–429. doi: 10.5603/PiAP.2014.0055 CrossRefPubMedGoogle Scholar
  36. Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, Kobayashi K, Ohara S, Kajiwara M, Matsubara A (2014) Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Lett 8(2):881–885, Epub 2014 Jun 2PubMedPubMedCentralGoogle Scholar
  37. Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T (2015) The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer 51(5):610–619. doi: 10.1016/j.ejca.2015.01.002. Epub 2015 Jan 21CrossRefPubMedGoogle Scholar
  38. Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M (2014) C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 111(1):55–60. doi: 10.1038/bjc.2014.277, Epub 2014 May 29CrossRefPubMedPubMedCentralGoogle Scholar
  39. Wang G, Li N, Cao L, Chen S, Guo L, Su K, Li F, Cui H, He J, Dai M, Zou Y, Sun D, Wu S (2014) [Association between the level of high sensitivity C-reactive protein and risk of breast cancer among non-diabetic females: a prospective study in Kailuan group]. Zhonghua Zhong Liu Za Zhi 36(12):944–948PubMedGoogle Scholar
  40. Xu L, Zhao Q, Huang S, Li S, Wang J, Li Q (2015) Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients. Tumour Biol 36(2):669–673. doi: 10.1007/s13277-014-2670-x, Epub 2014 Oct 7CrossRefPubMedGoogle Scholar
  41. Zeng YC, Wu R, Xiao YP, Chi F, Xue M, Zhang ZY, Xing R, Zhong WZ, Wang SL, Tian X, Chen W, Chen JJ, Wu LN (2015) Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Curr Oncol 22(1):20–24. doi: 10.3747/co.22.2178 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Zheng TL, Cao K, Liang C, Zhang K, Guo HZ, Li DP, Zhao S (2014) Prognostic value of C-reactive protein in esophageal cancer: a meta-analysis. Asian Pac J Cancer Prev 15(19):8075–8081CrossRefPubMedGoogle Scholar
  43. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y (2014) C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control 25(10):1397–1405. doi: 10.1007/s10552-014-0445-8, Epub 2014 Jul 23CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Waliza Ansar
    • 1
  • Shyamasree Ghosh
    • 2
  1. 1.Department of ZoologyBehala CollegeKolkataIndia
  2. 2.National Institute of Science EducationSchool of Biological SciencesBhubaneswarIndia

Personalised recommendations